AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01199562 — intervention group
Intervention type: PROCEDURE
Intervention: management of therapy complications
Description: undergo infection prophylaxis and management
Study NCT02009046 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SEI Classroom Curriculum
Description: Participants receive the 12-session Sexuality Education Initiative (SEI) classroom curriculum. The SEI classroom curriculum covers anatomy, abstinence, contraception and protection, STIs and HIV/AIDS, media messages, gender, relationships, rights and responsibilities, pregnancy, sexuality, peer pressure, negotiation and coercion, and decision making. These sessions are delivered over a two-month period. Each curriculum session is about 45 minutes in length.
Study NCT02009046 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Classroom Curriculum
Description: Participants receive the 3-session basic control curriculum. The control curriculum includes 3 sessions on sexually transmitted infections, anatomy and birth control delivered over a two- or three-week period. Each curriculum session is about 45 minutes in length.
Study NCT02009046 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SEI Curriculum + 3 School Components
Description: Participants receive SEI classroom curriculum and all three school wide components. The peer education/advocacy component recruits, trains and supervises students through an after-school leadership program to serve as resources to peers, organize health events, and refer students to school-based clinic services. The parent education component provides sessions for parents of students, covering reproductive health, teen pregnancy, and parent-teen communication, together with a parent education booklet for widespread use. The clinical services linkages includes health services on campus, including pregnancy/STI testing, contraceptive consultation and prescriptions, condom distribution, counseling, and referrals. It includes training for teachers and staff to distribute condoms as needed.
Study NCT02009046 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Curriculum + 1 School Component
Description: Participants receive control classroom curriculum and one of the three school wide components, the clinical services linkages. This component includes health services on campus for students, including pregnancy and STI testing, contraceptive consultation and prescriptions, condom distribution, counseling, and referrals. It also includes training for teachers and school staff to distribute condoms to students as needed.
Study NCT00844272 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: Group-therapeutic intervention with 12 sessions plus 5 update sessions with 24-week therapy duration and/or 12 sessions plus 10 update sessions with 48-week therapy duration Module I: Create understanding, resources, problems and solutions Module II: Information on hepatitis C infection Module III: Information on treatment Module IV: Specific information on depression and withdrawal symptoms under interferon The meetings take a minimum of 60 min. time, should be once weekly. The group size should lie between 6 and 12 participants.~The group leaders are trained in performance of the psycho-education.
Study NCT01909349 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-regulation
Description: Web-based support for behavior change regarding physical activity and fruit \& vegetable consumption
Study NCT01199562 — intervention group
Intervention type: DRUG
Intervention: ganciclovir
Description: Given IV
Study NCT01199562 — intervention group
Intervention type: DRUG
Intervention: valganciclovir
Description: Given orally
Study NCT01199562 — intervention group
Intervention type: DRUG
Intervention: foscarnet sodium
Description: Given orally
Study NCT01199562 — intervention group
Intervention type: PROCEDURE
Intervention: antiviral therapy
Description: undergo infection prophylaxis and management
Study NCT01199562 — intervention group
Intervention type: GENETIC
Intervention: polymerase chain reaction
Description: Correlative studies
Study NCT01199562 — intervention group
Intervention type: GENETIC
Intervention: protein expression analysis
Description: Correlative studies
Study NCT03086486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: Scored 600mg tablets
Study NCT02541734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gelofusine
Description: Infusion of gelofusine
Study NCT02541734 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 111In-exendin 4 SPECT/CT
Description: 111In-exendin 4 SPECT/CT
Study NCT02541734 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: 111In-exendin 4 SPECT/CT
Description: 111In-exendin 4 SPECT/CT
Study NCT02541734 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02268994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferric citrate
Description: 1 g ferric citrate containing approximately 210 mg of ferric iron
Study NCT02268994 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT01670773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-1004
Study NCT01670773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salsalate + DHA
Study NCT04515550 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: lumbar puncture
Description: Some participants will have an optional lumbar puncture
Study NCT01670773 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05266391 — intervention group
Intervention type: OTHER
Intervention: subacromial corticosteroid injections
Description: Patients with SAIS whose application of corticosteroid in their injections were the same in terms of type and dose (1 ml betamethasone dipropionate + betamethasone sodium phosphate).
Study NCT04770792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate with mineral trioxide aggregate.
Description: 2% chlorhexidine gluconate with mineral trioxide aggregate.
Study NCT04770792 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mineral trioxide aggregate.
Description: Mineral trioxide aggregate.
Study NCT00267852 — intervention group
Intervention type: OTHER
Intervention: as clinical practice
Description: Dosage, form, frequency and duration as per ordinary clinical practice
Study NCT02524418 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cholangiopancreatoscopy
Description: An ERCP with cholangioscopy/pancreatoscopy will be performed using the Spyglass DS. Clinical outcomes will be collected and analyzed.
Study NCT03665272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: deepithelialized gingival graft fixation
Description: one group's deepithelialized gingival graft fixed by sutures and other one's by tissue adhesive.
Study NCT03125772 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAXUS Element™ Paclitaxel-Eluting Stent System
Description: Texus Element is the next generation Boston Scientific paclitexel-eluting coronary sten and received DCGI approval on April 13th, 2010.
Study NCT03125772 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience PRIME Everolimus-Eluting Stent System
Description: The Everolimus-eluting stent manufactured and distributed by Abbott Vascular Santa Clara, CA, as Xience Prime.
Study NCT02872272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with Amikacin
Description: Aminoglycosides. Blood sampling for pharmacokinetic evaluation
Study NCT04534270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin will be given 5mg per day (weight≤30kg) or 10mg per day (weight>30kg), for 12 weeks
Study NCT02356692 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: enfilcon A
Description: Test lens
Study NCT02356692 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: enfilcon A
Description: Test lens
Study NCT00980759 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: EFI
Description: Para-aortic and Pelvic Irradiation with chemotherapy(cisplatin)
Study NCT00980759 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pelvic RT
Description: Only Pelvic Irradiation with chemotherapy(cisplatin)
Study NCT02037906 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Escalating Energy SWL
Description: Dose escalation, 1500 SW at 18 kv, followed by 1500 SW at 20 kv and the following 1500 SW at 22 kv.
Study NCT02037906 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Constant Energy SWL
Description: Constant dose at 20 kv
Study NCT02037906 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Reduction Energy SWL
Description: Dose reduction, 1500 SW at 22 kv, followed by 1500 SW at 20 kv and the following at 18 kv.
Study NCT03473899 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rESWT
Description: rESWT will be performed as follows:~* Nine rESWT sessions~* Three sessions per week~* rESWT device: Swiss DolorClast (Electro Medical Systems, Nyon Switzerland), EvoBlue handpiece, 15 mm applicator~* 2500 rESWs per session, with energy density between 0.12 and 0.16 mJ/mm\^2, depending on what the patient tolerates~* rESWs applied at 15 Hz~* Application of rESWs in prone position, with the patient lying on an examination table~* Exact location of the application of rESWs determined by clinical and ultrasonographic examinations~* Treatment of both the side of injury and the entire affected muscle (from distal to proximal in order to relax the affected muscle)~* No use of local anesthesia.~In addition, patients will receive a specific rehabilitation program.
Study NCT03473899 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham-rESWT
Description: Sham-rESWT will be performed as rESWT described in Arm rESWT + RP, but with a specially designed placebo EvoBlue handpiece that looks and sounds like the EvoBlue handpiece of the Swiss DolorClast, but does not generate radial shock waves. This is achieved by blocking the projectile shortly before it strikes the metal applicator. The placebo EvoBlue handpiece will not emit any radial shock wave energy.~In addition, patients will receive a specific rehabilitation program.
Study NCT03866564 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Cardiac ultrasound to measure left ventricular systolic function.
Study NCT03866564 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological Testing
Description: Standard clinical testing designed to establish or exclude the presence of cognitive dysfunction.
Study NCT03866564 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative Sensory Testing
Description: Clinically accepted quantitative assessment of chronic pain burden.
Study NCT03866564 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Nocturnal Polysomnography
Description: Routine overnight sleep study to measure apnea-hypopnea index.
Study NCT03086486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: 100mg tablets
Study NCT03086486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Linezolid
Description: Scored 600 mg tablets
Study NCT04413110 — intervention group
Intervention type: DEVICE
Intervention: Polysomnography
Description: PSG was carried out for 41 patients with subjective cognitive impairment and 41 age and sex-matched controls. PSG with standard EEG montage that includes bilateral EOG and four EEG leads were used. A single attended overnight PSG study was performed at the Clinical Neurophysiology Unit of Mansoura University Hospitals. Patients were studied in a quiet, darkened room with no medications were used to induce sleep. All participants underwent one night of laboratory-based PSG.
Study NCT01807312 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic CO2 regulation unit and accessories
Description: Olympus UCR Endoscopic CO2 Regulation Unit
Study NCT01807312 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02233439 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Herbal galactagogue
Study NCT02233439 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00611546 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Photo-protection
Description: Parenteral solutions are protected from day light using aluminum covers
Study NCT00611546 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Photo-exposure
Description: Perenteral nutrition bottles and tubings are allowed to be exposed to day light.
Study NCT02666729 — intervention group
Intervention type: PROCEDURE
Intervention: AF Ablation with contact force information
Description: Ablation procedure will be done using TactiCath Quartz ablation catheter which can measure the amount of contact force being used. Researcher will be made aware of contact force data when performing procedure.
Study NCT02666729 — intervention group
Intervention type: PROCEDURE
Intervention: AF Ablation without contact force information
Description: Ablation procedure will be done using TactiCath Quartz ablation catheter which can measure the amount of contact force being used. Researcher will not be made aware of contact force data when performing procedure.
Study NCT01837134 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: telemedical (TM) group
Description: telemedical devices (weighing machine and step counter)
Study NCT01837134 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telemedical coaching (TMC) group
Description: care calls once per week for 12 weeks
Study NCT04177446 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: a production consist of various oligopeptides and the whey protein
Description: patients will be given extra protein intake except the basic energy intake
Study NCT04177446 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: basic energy intake
Description: supplement as basic energy intake
Study NCT04177446 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: basic energy intake
Description: supplement as basic energy intake
Study NCT04177446 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: maltodextrin
Description: used as placebo in the control group
Study NCT02083627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Description: Oral
Study NCT02083627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fidaxomicin
Description: Oral
Study NCT02289872 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macintosh Laryngoscope
Description: Direct-Laryngoscopy
Study NCT02427776 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CD4+T cells stimulated and expanded ex vivo by a MOG peptide modified by the introduction of a thioreductase motif into the flanking residues of the T cell epitope
Description: 1 administration comprising 5 - 50 millions of cells
Study NCT02173587 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mussel oil capsules
Description: Each mussel oil capsule contained 200mg thick shell mussel lipid extract and 200mg corn oil.Each patient in this group received daily four mussel oil capsules (containing 800mg mussel oil and 800mg corn oil) for first two months and two mussel oil capsules per day thereafter
Study NCT02173587 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Corn oil capsules
Description: Each corn oil capsule contained 400mg corn oil.Each patient in this group received daily four corn oil capsules (1600mg corn oil) for first two months and two corn oil capsules per day thereafter
Study NCT00724633 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Lowering the dialysate sodium
Description: Please see above
Study NCT00724633 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lowering the dialysate sodium
Description: Please see above
Study NCT04635514 — intervention group
Intervention type: PROCEDURE
Intervention: Lateral colporrhaphy
Study NCT03857542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine HCl Ophthalmic Solution
Description: Pilocarpine HCl ophthalmic solution 1.25%, one drop in each eye, once daily, for up to 30 days.
Study NCT03857542 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle, one drop in each eye, once daily, for up to 30 days.
Study NCT04412707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: Peripheral versus central administration
Study NCT04412707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Oral tablets
Study NCT01548196 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard Percutaneous nephrolithotomy
Description: Percutaneous nephrolithotomy
Study NCT05532280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg film coated tablet
Description: an immediate-release tablet containing 90 mg of Etoricoxib
Study NCT05532280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arcoxia 90 mg film coated tablet
Description: an immediate-release tablet containing 90 mg of Etoricoxib
Study NCT00924339 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soy protein diet
Description: Intervention-Group (n = 15): Fat- modified dietary regime and a minimum amount of soy protein: 0,25 g/ kg BW/d
Study NCT00924339 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: rapeseed oil
Description: Control-Group (n = 15): Diet reduced in SFA, modified in fatty acid pattern. Only rapeseed oil should to be used for preparation of the meals (baking, frying, in salad, and as spread.
Study NCT02356692 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A
Description: Control lens
Study NCT02356692 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: Control lens
Study NCT02413541 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Polymyxin-B Hemoperfusion
Description: Endotoxin removal
Study NCT02413541 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard treatment
Study NCT02413541 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Study NCT02159521 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EkoSonic® Endovascular System
Study NCT02159521 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alteplase
Description: Recombinant tissue plasminogen activator
Study NCT03265197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-tympanic injection of drugs
Description: Intratympanic injection of combined lidocaine and dexamethasone in treatment of tinnitus
Study NCT03265197 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Data management of intratympanic drugs
Description: intervention by statistical analysis of Intratympanic injection of combined lidocaine and dexamethasone in treatment of tinnitus
Study NCT00490074 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DNA-C
Description: 1.0mg per ml of DNA HIV-C vaccine 2x2 ml IM
Study NCT00490074 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA-C
Description: 1.0mg per ml of DNA HIV-C vaccine 2x2 ml IM
Study NCT00490074 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NYVAC-C
Description: NYVAC-C 1 ml IM
Study NCT00490074 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NYVAC-C
Description: NYVAC-C 1 ml IM
Study NCT02202369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal Analgesia Treatment
Description: Subjects are given medications preop (Pregabalin, Oxycodone, Acetaminophen, Transdermal Scopolamine, Cyclobenzaprine), intraop (Propofol induction, Sevoflorane maintenance, Dexamethasone, Fentanyl, Ketamine, Marcaine, Zofran) and postop(Acetaminophen, Pregabalin, Tramadol, Cyclobenzaprine) that implement a multi-modal approach to managing pain.
Study NCT02202369 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Pain Management Protocol
Description: Subjects will be treated with patient controlled (standard of care) narcotic analgesia for pain management. (Marcaine, Dexamethasone, Zofran, Morphine, Acetaminophen, Cyclobenzaprine)
Study NCT01900808 — intervention group
Intervention type: DEVICE
Intervention: Trained operator with M probe.
Description: Trained operator with M probe: non-drug intervention, baseline comparator.
Study NCT02181062 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking Intervention
Description: 4-week series of twice-weekly 1-hour group-based case-manager-led interactive sessions.~The intervention will provide the knowledge necessary to improve stroke risk factors. Case manager group leaders will teach that seeing a healthcare provider regularly and monitoring blood pressure prevents strokes; all participants will be provided with the National Institute on Aging booklet, How to Talk to your Doctor and the contact information for their healthcare provider.~Participants will be given a pedometer and be trained to use it to measure steps, with the goal of reaching 10,000 steps each day.~The intervention will utilize attribution retraining to teach seniors that stroke risk factors including sedentary lifestyle should not be attributed to old age.
Study NCT00776646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide 50 mg tablet
Study NCT01900808 — intervention group
Intervention type: DEVICE
Intervention: Experienced operator with M probe.
Description: Experienced operator with M probe: non-drug intervention, longitudinal comparator.